Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, ...
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...
Dow Jones Top Company Headlines at 11 AM ET: Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera | Mounjaro ... Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for ...
Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound. Q3 2025 EPS increased by $5.14 to $6.21 on a reported ...
The S&P 500 fell 0.3% to 5,018. Nasdaq sank 0.6% to 15,170 as Meta plunged 11% after weak ad revenue guidance. Microsoft ...
A woman has taken to the internet to share the biggest difference she experienced when switching between GLP-1 drugs Wegovy ...
Shares of the world's largest healthcare company by market value were up nearly 2% in morning trading even as investors remain wary of drug price negotiations with the Trump administration.
Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...
InvestorsHub on MSN
Eli Lilly Raises Full-Year Guidance on Soaring Demand for Weight-Loss Drugs
Eli Lilly (NYSE:LLY) raised its full-year outlook on Thursday after delivering third-quarter results that handily beat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback